Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Breast Neoplasms 346Neoplasms 247Prostatic Neoplasms 198Colorectal Neoplasms 151Lung Neoplasms 130Carcinoma, Non-Small-Cell Lung 108Leukemia, Myeloid, Acute 107Pancreatic Neoplasms 98Multiple Myeloma 89Glioblastoma 77Precursor Cell Lymphoblastic Leukemia-Lymphoma 73Brain Neoplasms 73Head and Neck Neoplasms 72Carcinoma, Hepatocellular 67Squamous Cell Carcinoma of Head and Neck 65Melanoma 62Uterine Cervical Neoplasms 61Ovarian Neoplasms 59Neoplasm Metastasis 55Rectal Neoplasms 52Hematologic Neoplasms 50Recurrence 48Stomach Neoplasms 47Glioma 46Myelodysplastic Syndromes 45Motor Activity 45Triple Negative Breast Neoplasms 44Carcinoma, Renal Cell 44Endometrial Neoplasms 43Sarcoma 41

Interventions

11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gastro-enteropancreatic neuroendocrine tumor × 30 days × Clear all
NCT05988918 2026-05-14

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

University of Michigan Rogel Cancer Center

Phase 2 Active not recruiting
17 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell, Somatostatinoma, Carcinoma, Adenosquamous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡